Fogyma oral solution for iron deficiency anemia (4 blisters x 5 tubes)

Dosage form Oral solution
Specifications Box 4 blister x 5 tubes x 10ml
Ingredient Elemental iron
Indication Iron anemia, anemia
Contraindication Excess iron

Ingredient

Thành phần cho 10ml

Composition informationContent
Elemental iron50mg

Uses

indications

Fogyma is indicated in the following cases:

Iron supplementation for patients at risk of iron deficiency anemia such as:

Pregnant women.

breastfeeding women.

malnutrition.

Personal after surgery.

Children anemia due to iron deficiency, growth slowly, stunted.

Pharmacology

iron complex (III) Hydroxyd polymaltose (IPC): iron salts, including IPC, plays an important role in treatment as well as infrequent iron deficiency anemia. The body reserves iron in the form of ferritin and hemosiderin to create hemoglobin.

IPC's iron (III) hydroxyd is surrounded by many polymaltose molecules that form a large molecule with a molecule of about 52300 Dalton, so large that its diffusion through the mucosal membrane is less than iron salt (II) about 40 times.

iron in IPC nucleus is linked to the same structure as Ferritin. IPC is different from iron form (II) sulfate thanks to high safety and low toxicity due to no free iron ions. IPC is a complex of iron (III) hydroxid combined with polymaltose.

Its iron ionized ionization helps the stomach are less irritated than conventional iron salts, helping patients tolerated better, a very important point in the long -term treatment of iron deficiency anemia with iron -containing preparations.

The effectiveness of IPC in the prevention and treatment of iron deficiency anemia has been proven in clinical trials. Hemoglobin value increases faster when using IPC compared to conventional iron salts. When using IPC, the hemoglobin value increased to 0.8 mg/dL per week. In addition, there is a faster increase than hematocrit, MCV, serum and ferritin.

Dynamic pharmacokinetics

The absorption of iron ion (III) from iron (III) Hydroxyd Polymaltose is a physiological process. When the IPC complex is exposed to the positions associated with iron on the mucosal surface, it will release iron ions (III) and are actively transported into the mucosa cells by a membrane protein and then linked to ferritin or transferrin.

Proteins include mucin, integrin and mobilferrin. Iron is released from membrane proteins and is stored in mucosal cells in the form of ferritin or carried by the proteins carrying the blood and there is released to combine with transferrin.

The bioavailability of IPC complex is equivalent to iron salt (II) in experimental animals and in people with hemoglobin synthesis. IPC's bioavailability when taken is not affected by food ingredients such as phytic acid, oxalic acid, tannin, sodium alginate, cholin salt, vitamin A, D3, E, soybean oil and flour, unlike conventional iron salts.

The iron in the IPC complex enters the serum thanks to endogenous proteins, with a semi -discharged time about 90 minutes, then goes into the liver's endothelium or combined with transferrin, apoferritin, bone marrow or spleen to create red blood cells. The cohesive antacids can be separated from IPC within 3 to 8 pH, different from inorganic iron salts that are unable to sustainable. There is no interaction between hormones and IPC (like regular iron medications).

When iron passes through the fence of the velvet, it is associated with the transferrin, each transferrin element can be attached to two iron atoms. Normally about 20 - 45% of the locations are cohesive. The specific receptors of the cell membrane recognize the transferrin, allowing this complex to enter the cell and release iron into the cytoplasm.

iron in regular iron preparations is iron II ions, which can easily cause stomach irritation. The absorption of iron ions II is passive and uncontrolled, which can cause excess iron and toxic to the body. IPC has better safety and iron in the form of no ionization that is less irritating to the stomach, and has little pharmacokinetic interaction with other substances like conventional iron salts.

Before taking Fogyma oral solution for iron deficiency anemia (4 blisters x 5 tubes)

How to use

Take oral use.

Dosage and treatment time depend on the level of iron deficiency.

Daily dose can be divided into small or disposable doses. Fogyma should be taken in or immediately after eating.

Remove plastic tubes and drink directly in the pipe, can be diluted with water or drink water after use.

Dosage

Adults and children over 12 years: Take 1 tube/time x 2 times/day.

Children under 12 years: Take 1 tube/time x 1-2 times/day.

or as directed by the doctor for each specific case.

In case there is a significant sign of iron deficiency, it is necessary to treat for about 3-5 months until the value of hemoglobin returns to normal. After that, it is necessary to continue treating for a few weeks with the indications for potential iron deficiency to supplement the amount of iron reserves.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when using overdose? Fogyma is generally safe.

The comparative studies between iron (II) sulfate and iron (III) Hydroxyd polymaltose on the mouse also identify the LD50 of iron (II) sulfate as 350 mg/kg, but there is no disease or death in the IPC group with doses of over 1000 mg/kg.

IPC's iron absorption is less, but IPC has better gastrointestinal intake, along with a higher IPC safety, which can be important to reduce the risk of iron overdose. Although IPC is safer than iron salts (II) inorganic, can still overdose but rare. Symptoms of iron overdose include fatigue, nausea, vomiting, abdominal pain, stools such as darkness, fast and weak pulse, fever, coma, convulsions and death. Need emergency immediately if iron overdose.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Fogyma, you may experience unwanted effects (ADR).

Fogyma is well tolerated, unwanted effects are less common than inorganic iron preparations. Because IPC provides iron in non -ionized form, it is less irritating to the stomach than inorganic iron salts.

Common, ADR> 1/100

digestive: epigastric pain, metal taste, nausea or vomiting, abnormalities, constipation, diarrhea, black stool.

Teeth: Sometimes tooth color changes.

Uncommon, 1/1000

No report.

Instructions on how to handle ADR

Notify the doctor with unwanted effects when taking the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Fogyma drugs contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Anemia is not due to iron deficiency (hemolytic anemia, red blood cell disorders, bone marrow production).

Excess iron.

Be cautious when used

Overdose of iron -containing drugs that can cause poisoning leading to death in children under 6 years old. Although Fogyma is quite safe because the IPC has very high LD50, it must be left for the medicine at the reach of children. If you accidentally overdose, call your doctor or the anti -toxic center immediately.

Iron -containing drugs, including iron (III), hydroxyd polymaltose, can cause allergic reactions or anaphylaxis. If allergic reactions, fogyma must be stopped and applied emergency measures.

Do not overdose indicated. The treatment of anemia must follow the instructions and monitoring of the doctor. Sometimes discomfort in the gastrointestinal tract (such as nausea), can be minimized by taking medication during meals. Iron drugs can cause constipation or diarrhea.

Be cautious when used for people with allergies, liver failure or kidney failure.

Be cautious when used for alcoholics and people with gastrointestinal diseases such as gastrointestinal ulcers, colitis.

The ability to drive and operate machinery

no.

Pregnancy

The product is indicated for pregnant and lactating women in cases where there is a risk of iron deficiency anemia.

The period of breastfeeding

The product is indicated for pregnant and lactating women in cases where there is a risk of iron deficiency anemia.

Drug interaction

Because iron in IPC is in the form of complex links, the interactions between iron ions and ingredients of food (such as phytin, oxalate, tannins, etc. ...) and other oral medications (tetracyclin, antacids) are rarely occur. Like other iron drugs, IPC can also reduce the absorption of some drugs. IPC should not be taken within 2 hours after taking the following drugs: Tetracyclin, fluoroquinolon, chloramphenicol, cimetidine, levodopa, levothyroxin, methyldopa or penicillamine.

The cohesive antacids can be separated from IPC within 3 to 8 pH, different from inorganic iron salts, which are sustainable binding, but antacids can reduce IPC absorption. Do not take antacids within 2 hours after using IPC. There is no interaction between hormones and IPCs (like conventional iron medications).

Storage

Storage in closed packaging, avoid moisture, avoid light, temperature below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

count views

Popular Keywords